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Background:  Despite  a promising  association  between  VF  waveform  characteristics  and  prognosis  after
resuscitation,  studies  with  VF-guided  treatment  have  so  far not  improved  outcomes.  While  driven  by
the  idea  that  the  VF  waveform  reﬂects  arrest  duration,  increasing  evidence  suggests  that pre-existent
disease-related  changes  of the myocardium  affect  ECG-characteristics  of  VF as  well.  In  this  context,  we
studied the  impact  of  the left  ventricular  (LV)  diameter  and mass.
Methods:  Cohort  of  193  ICD-patients  with  deﬁbrillation  testing  at the  Radboudumc  (2010–2014).  Surface
ECG-recordings  (leads  I,II,aVF,V1,V3,V6)  were  analysed  to study  amplitude  and  frequency  characteris-
tics  of  the  induced  VF.  Both  for  LV  diameter  and  mass,  patients  were  categorised  in two  groups,  using
echocardiographic  data  (ASE-guidelines).
Results:  In all  ECG-leads,  dominant  and  median  frequencies  were  signiﬁcantly  lower  in patients  with
(n = 40)  than  in  patients  without  (n  = 151)  an increased  LV  diameter.  The  mean  amplitude  and  amplitude
spectrum  area  (AMSA)  did  not  differ.  In contrast,  we observed  no  differences  in  frequency  characteristics
in  relation  to the  LV  mass,  whereas  mean  amplitude  (I,aVF,V3)  and  AMSA  (I,V3)  were  signiﬁcantly  higher
in patients  with  (n  =  57)  than  in  patients  without  (n  = 120)  an  increased  LV  mass.
Conclusions:  Frequency  characteristics  of  VF  were  consistently  lower  in  case  of  an  increased  LV  diame-
ter.  Whereas  LV  mass  does  not  affect  the frequency  of  the VF waveform,  amplitudes  seem  higher  with
increasing  mass.  These  ﬁndings  add  to the  current  knowledge  of  factors  that  modulate  VF  characteris-
tics  of the surface  ECG  and  provide  insight  into  factors  which  may  be  accounted  for  in future  studies  on
VF-guided  resuscitative  interventions.
© 2018  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Over the years, various initiatives have been taken to improve
outcome after out-of-hospital cardiac arrest (OHCA) [1,2]. For
patients with ventricular ﬁbrillation (VF), one of the proposed
strategies involves guidance of chest compressions and shock deliv-
eries based on analysis of the VF waveform [2–5].
∗ Corresponding author at: Radboud University Medical Center, Department of
Cardiology 616, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
E-mail addresses: judithbonnes@gmail.com, Judith.Bonnes@radboudumc.nl (J.L.
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This idea was  based on early observations that the VF wave-
form of the electrocardiogram (ECG) reﬂects arrest duration, and
evolves from coarse to ﬁne with worsening of the myocardial
metabolic state [6]. In this context, it has been thought that
patients with longer arrest durations may  beneﬁt from a chest
compression-ﬁrst strategy, instead of immediate shock therapy, to
improve myocardial readiness for deﬁbrillation [3–5,7]. However,
randomised studies comparing these strategies in the OHCA set-
ting, whether or not guided by VF analysis, could not substantiate
survival beneﬁt [8,9].
More recent evidence indicates that the appearance of the VF
waveform of the surface ECG not only reﬂects arrest duration, but
is also affected by the underlying cardiac disease [10–12]. In ani-
mals, VF frequency characteristics have consistently been shown to
https://doi.org/10.1016/j.resuscitation.2017.03.029
0300-9572/© 2018 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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be lower in the presence than in the absence of an acute myocar-
dial infarction (MI) [10,11]. In contrast, studies in OHCA-patients
yielded inconsistent results with regard to the impact of an acute
MI [13–15]. Besides acute factors, there is robust evidence in both
patients and animals that pre-existent cardiac disease affects VF
characteristics as well [12,16–18]. Previous studies primarily inves-
tigated the impact of infarction, while there is scarcity of data
on the effect of other pre-existent disease-related changes of the
myocardium on VF characteristics [16–18].
Improved understanding of factors that inﬂuence the appear-
ance of the VF waveform of the surface ECG may  help to unravel
whether and how VF analysis could be helpful to guide resuscitative
interventions. In this context, we studied induced VF characteristics
of the surface ECG in relation to the left ventricular (LV) diame-
ter and mass in patients who underwent implantable cardioverter
deﬁbrillator (ICD) implantation.
Methods
Patient population
From a registry of ﬁrst ICD implantations at the Radboud Uni-
versity Medical Center, we identiﬁed all patients who  underwent
deﬁbrillation testing from June 2010-January 2014. We  included
patients for whom the following was available: 1) A 12-lead sur-
face ECG of the induced VF; 2) A complete echocardiographic
assessment prior to ICD implantation. Exclusion criteria were: age
<18 years, congenital heart disease and right-sided ICD implants.
Given the observational design of the study, written informed con-
sent was not necessary to obtain according to the Dutch Act on
Medical Research involving Human Subjects.
ICD implantation and testing
The devices implanted were Medtronic (Minneapolis, Minn,
USA), St Jude Medical (St. Paul, Minn, USA) or Biotronik (Berlin,
Germany) ICD or cardiac resynchronisation therapy-deﬁbrillator
systems with transvenous single coil leads. Routine deﬁbrillation
testing was performed after ICD implantation to test the ability of
the implanted device to sense, detect and terminate VF appropri-
ately. After sedation with propofol, VF was induced using T-wave
shock, direct current pulses or 50 Hz burst pacing. The presence of
VF, deﬁned as a rapid (around 300 bpm) grossly irregular ventricu-
lar rhythm with marked variability in QRS cycle length, morphology
and amplitude, was conﬁrmed on surface ECG recordings [19]. The
ICD was programmed to deliver sequential shocks (15–25–35 J)
until VF was terminated. In case of persisting VF after the third
shock, an external deﬁbrillation shock was delivered.
Clinical and echocardiographic parameters
Data regarding demographics and medical histories were col-
lected from patient records. The underlying cardiac aetiology was
determined using patient charts. In the presence of a previous
MI,  we crosschecked the MI  localisation using ECGs and imaging
reports (i.e. echo, nuclear scan, MRI), as described previously [18].
LV diameter and mass
Echocardiographic measurements of the LV internal diastolic
diameter (LVIDd) and mass were collected from imaging reports.
Both measurements had been done as part of the work-up for
ICD implantation according to local standards. Measurements were
indexed to body surface area and categorised using gender-speciﬁc
thresholds as recommended by the American Society of Echocar-
diography [20]. Echocardiography had to be performed within one
year before ICD implantation and without intercurrent cardiac
events.
VF waveform characteristics
ECG recordings
During deﬁbrillation testing, a standard 12-lead ECG of the
induced VF was recorded (sampling frequency 1000 Hz; 16-bit A/D
converter) with BARD LabSystem Pro (Lowell, Massachusetts, USA).
Lead I, II, aVF, V1, V3 and V6 were selected for VF analysis, as these
represent the main electrical vectors and include uni- and bipolar
leads.
VF waveform analysis
VF waveform characteristics were determined using a time
segment of 4.1 s prior to ﬁrst shock delivery (4096 time-points).
The signal was  pre-processed with a 2 Hz high-pass ﬁlter and a
20 Hz low-pass ﬁlter. We  analysed several previously studied VF
characteristics [5,21,22]. From the ECG-signal in the time domain,
we determined the mean absolute amplitude. Subsequently, the
signal was  converted to the frequency domain by using a fast
Fourier transform to visualize the frequencies and correspond-
ing amplitudes, which the sampled VF signal contains [5]. From
the amplitude frequency spectrum, the amplitude spectrum area
(AMSA) was  calculated as the summed product of individual fre-
quencies and their corresponding amplitudes over an interval of
2–20 Hz [21,22]. From the power spectrum, we determined the
dominant frequency, which is the frequency where the power spec-
trum attains its maximum [5]. In addition, we determined the
median frequency, i.e. the frequency for which the integrated sig-
nal power was  one half of the total integrated power. Finally, we
calculated the bandwidth, which is the difference in frequency
corresponding to the ﬁrst and third quartile of the total power, pro-
viding a measure of the spread in frequencies [22]. Deﬁnitions of the
analysed VF characteristics are described in detail in the Appendix.
Calculations were performed using Matlab (version 2011a, Math-
works, Natick, MA,  USA).
Outcome measures and deﬁnition of study groups
Outcome measures are the VF waveform characteristics as
described above. For analyses on the LV diameter, we compared
two groups: 1) patients with normal LV diameters or with LV
diameters that indicated mild dilatation versus 2) patients with
moderate to severely increased LV diameters [study groups: nor-
mal  vs. increased LV diameters (≥3.5 cm/m2)]. For analyses on the
LV mass, we compared two  groups as well: 1) patients with nor-
mal  LV masses or with masses that indicated mild hypertrophy
versus 2) patients with moderate to severely increased LV masses
[study groups: normal vs. increased LV masses (males: ≥132 g/m2;
females: ≥109 g/m2)].
Statistical analysis
Statistical analyses were performed with IBM SPSS statistics
software (version 22, IBM Corp., Armonk, NY, USA). Categorical
data are expressed as numbers (percentages). Continuous base-
line variables are expressed as means ± standard deviations. The
VF waveform characteristics are presented as medians (interquar-
tile ranges (IQRs)) and were compared using the Mann Whitney U
test. A p-value of <0.05 was considered statistically signiﬁcant. To
provide an indication whether the effect of the LV diameter and
mass on the outcomes measures was independent of other fac-
tors, we  performed multivariate linear regression analyses using
data of surface ECG-lead I. This lead was  chosen in view of the
similarity with the paddle-ECG recorded during resuscitations. The
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Table 1
Clinical characteristics of patients with normal and increased LV diameters.
Normal LV
diameter
n = 151
Increased LV
diameter
n = 40
P-value
Age (yrs) 63 ± 12 62 ± 14 0.663
Male gender 123 (82) 22 (55) 0.001
Hypertension 61 (41) 14 (35) 0.515
Diabetes 36 (24) 9 (23) 0.843
Atrial ﬁbrillation 50 (33) 10 (25) 0.326
Previous MI 89  (59) 22 (55) 0.653
BMI  (kg/m2) 27 ± 4 25 ± 4 0.039
Secondary prevention 59 (39) 4 (10) 0.001
CRT-D 44 (29) 17 (43) 0.107
LVEF (%) 38 ± 14 28 ± 9 <0.001
LVIDd-index (cm/m2) 2.8 ± 0.3 3.8 ± 0.3 <0.001
LV  mass index (g/m2) 110 ± 29 132 ± 30 <0.001
QRS duration (ms)* 112 (94–122) 111 (102–125) 0.374
QTc  duration (ms)* 455 (423–483) 455 (423–480) 0.968
Creatinine (mol/l) 97 ± 54 137 ± 211 0.249
Beta  blocker 137 (91) 37 (93) 1.000
ACE inhibitor/ARB 129 (86) 38 (95) 0.173
Aldosterone blocker 59 (39) 20 (50) 0.224
Diuretics 69 (46) 28 (70) 0.007
Antiplatelet 91 (61) 20 (50) 0.224
Anticoagulation 66 (44) 16 (40) 0.650
Cholesterol reducer 100 (67) 28 (70) 0.690
Amiodarone 20 (13) 3 (8) 0.419
*In the absence of a typical bundle branch block. Values are n (%), means ± standard
deviations or medians (IQRs). ACE inhibitor: angiotensin converting enzyme
inhibitor, ARB: angiotensin receptor blocker, BMI: body mass index, CRT-D: cardiac
resynchronization therapy deﬁbrillator, LV: left ventricular, LVEF: left ventricular
ejection fraction, LVIDd: left ventricular internal diastolic diameter, MI:  myocardial
infarction.
mean amplitude and AMSA were log-transformed to approximate
a normal distribution. All confounding variables as well as variables
which have previously been associated with the outcome measure
of interest were offered to the models [16–18].
Results
Study group
A total of 337 adults underwent a ﬁrst left-sided ICD implanta-
tion with deﬁbrillation testing during the study period. In total, 144
patients were excluded for the following reasons: no analysable 12-
lead ECG of the induced VF (n = 131), missing echocardiographic
data (n = 13). Accordingly, a total of 193 patients were included in
the present analysis. Baseline characteristics did not differ between
the in- and excluded patient groups (Supplementary Table 1).
Patient characteristics
The mean age was 63 years ± 13 and 76% (146/193) was  male.
Mean left ventricular ejection fraction (LVEF) was 36% ± 14. In total
58% (111/193) of patients had a previous MI,  of which 41% (46/111)
was located in the anterior wall and 45% (50/111) in the inferior
wall. Of the patients without infarction (n = 82), LV dysfunction
was caused by cardiomyopathies, hypertension or valvular heart
diseases in 89% (73/82). Four percent (3/82) had a cardiac chan-
nelopathy and 7% (6/82) could not be classiﬁed. Further clinical
characteristics are summarised in Tables 1 and 2.
VF characteristics in relation to the LV diameter
Measurements of the LV diameter were available for 191
patients. In total, 79% (151/191) had a normal to mildly abnormal
indexed LV diameter, with a mean of 2.8 ± 0.3 cm/m2. In the 21%
(40/191) with a moderate to severely abnormal LV diameter, the
Table 2
Clinical characteristics of patients with normal and increased LV masses.
Normal LV mass
index
n = 120
Increased LV
mass index
n  = 57
P-value
Age (yrs) 62 ± 13 63 ± 13 0.618
Male gender 96 (80) 37 (65) 0.030
Hypertension 47 (40) 25 (44) 0.582
Diabetes 29 (24) 13 (23) 0.820
Atrial ﬁbrillation 34 (28) 22 (39) 0.170
Previous MI 71  (59) 31 (54) 0.548
BMI  (kg/m2) 27 ± 5 27 ± 3 0.975
Secondary prevention 46 (38) 13 (23) 0.041
CRT-D 32 (27) 23 (40) 0.066
LVEF (%) 38 ± 13 33 ± 13 0.018
LVIDd-index (cm/m2) 2.9 ± 0.4 3.3 ± 0.5 <0.001
LV  mass index (g/m2) 98 ± 19 147 ± 23 <0.001
QRS duration (ms)* 112 (94–124) 108 (101–123) 0.769
QTc  duration (ms)* 450 (421–480) 466 (445–502) 0.010
Creatinine (mol/l) 91 ± 38 127 ± 178 0.149
Beta blocker 108 (91) 52 (91) 0.919
ACE inhibitor/ARB 105 (88) 52 (91) 0.549
Aldosterone blocker 52 (44) 26 (46) 0.811
Diuretics 59 (50) 33 (58) 0.301
Antiplatelet 74 (62) 28 (49) 0.100
Anticoagulation 50 (42) 25 (44) 0.817
Cholesterol reducer 78 (66) 37 (65) 0.934
Amiodarone 13 (11) 7 (12) 0.791
*In the absence of a typical bundle branch block. Values are n (%), means ± standard
deviations or medians (IQRs). ACE inhibitor: angiotensin converting enzyme
inhibitor, ARB: angiotensin receptor blocker, BMI: body mass index, CRT-D: cardiac
resynchronization therapy deﬁbrillator, LV: left ventricular, LVEF: left ventricular
ejection fraction, LVIDd: left ventricular internal diastolic diameter, MI:  myocardial
infarction.
mean LVIDd index was  3.8 ± 0.3 cm/m2. Baseline characteristics are
presented in Table 1.
Frequency characteristics
In patients with an increased LV diameter, the dominant and
median frequencies were signiﬁcantly lower when compared to the
subset with a normal diameter in all analysed ECG-leads (Fig. 1).
Amplitude characteristics
The mean VF amplitude and AMSA did not differ between
patients with normal and increased LV diameters. This held true
for all analysed ECG-leads (Fig. 1).
The bandwidth did not differ between study groups in any lead
either.
Multivariate analysis
After correction for the LV mass, amiodarone and a previous
MI,  we found an independent association between the LV diameter
and the dominant and median frequencies of VF [ −0.324 (95% CI
−0.565 to −0.083) p = 0.009;  −0.291 (95% CI −0.513 to −0.069)
p = 0.010].
VF characteristics in relation to the LV mass
Measurements of the LV mass were available for 177 patients. In
total, 68% (120/177) had a normal to mildly abnormal indexed LV
mass, with a mean of 98 ± 19 g/m2. In the 32% (57/177) of patients
with a moderate to severely abnormal LV mass, the mean mass
index was  147 ± 23 g/m2. Baseline characteristics are presented in
Table 2.
Frequency characteristics
The dominant and median frequencies did not differ between
study groups, with the exception of a signiﬁcantly lower domi-
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Fig. 1. Impact of the LV diameter on VF waveform characteristics of the surface ECG.
VF  waveform characteristics are presented as medians with interquartile ranges. * P-value < 0.05. The dominant and median frequencies were signiﬁcantly lower in patients
with  an increased LV diameter when compared to those with a normal LV diameter. P-values dominant frequency: lead I: 0.006, lead II: 0.010, lead aVF 0.019, lead V1: 0.028,
lead  V3: 0.050, lead V6: 0.009. P-values median frequency: lead I: 0.008, lead II: 0.028, lead aVF: 0.032, lead V1: 0.027, lead V3: 0.017, lead V6: 0.006. The mean amplitude,
AMSA and bandwidth did not differ signiﬁcantly between patients with increased and normal LV diameters, in all leads (p-values > 0.05). AMSA: Amplitude Spectrum Area,
Hz:  Hertz, LV: left ventricular, mV:  millivolt.
nant frequency in lead V3 in the subset with an increased LV mass
compared to those with a normal LV mass (Fig. 2).
Amplitude characteristics
In patients with an increased LV mass, the mean VF amplitude
was signiﬁcantly higher in leads I, aVF and V3 when compared to
the subset with a normal LV mass (Fig. 2). In leads II and V6, the
mean amplitude was slightly higher as well (p < 0.1), but this did
not reach statistical signiﬁcance. No difference was  observed in lead
V1. In case of an increased LV mass, the AMSA was signiﬁcantly
higher in leads I and V3 as well. In leads II and aVF, the AMSA was
also slightly higher (p < 0.1). No difference was observed in lead V1
and V6.
The bandwidth did not differ between study groups in any lead
either.
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Fig. 2. Impact of the LV mass on VF waveform characteristics of the surface ECG.
VF  waveform characteristics are presented as medians with interquartile ranges. * P-value < 0.05. The dominant and median frequencies as well as the bandwidth did not differ
between study group, in all leads (p-values > 0.05), with the exception of the dominant frequency in lead V3 (p = 0.047). The mean amplitude and AMSA were signiﬁcantly
higher in patients with an increased LV mass compared to those with a normal LV mass in leads I, aVF and V3 and leads I and V3, respectively. P-values mean amplitude:
lead  I: 0.021, lead II: 0.050, lead aVF: 0.031, lead V1: 0.451, lead V3: 0.014, lead V6: 0.092. P-values AMSA: lead I: 0.047, lead II, 0.084; lead aVF: 0.060, lead V1: 0.282, lead
V3:  0.009, lead V6 0.144. AMSA: Amplitude Spectrum Area, Hz: Hertz, LV: left ventricular, mV:  millivolt.
Multivariate analysis
After correction for a previous MI,  gender and the LVEF, we
observed an independent association between the LV mass and
the log-transformed mean amplitude and AMSA [ 0.095 (95% CI
0.027–0.163), p = 0.006;  0.065 (95% CI 0.008–0.122) p = 0.026].
Discussion
Frequency characteristics of initial VF varied according to the LV
diameter, with consistently lower values in all ECG-leads in patients
with marked LV dilatation. Amplitude characteristics were not
related to the LV diameter. In contrast, VF frequency was not related
to the LV mass. While amplitude characteristics seemed higher in
case of an increased LV mass, this was  not consistent across all the
different ECG-leads. These ﬁndings add to the growing body of evi-
dence indicating that the VF waveform of the surface ECG is altered
by pre-existent disease-related changes of the myocardium, includ-
ing abnormal geometrics and infarcted areas [17,18]. In this light,
a more comprehensive concept of VF characteristics seems war-
ranted, which may  contribute to renewed insights into the potential
of VF analysis to guide resuscitative interventions.
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Table  3
Impact of patient-related factors on ECG characteristics of the VF waveform. In this Table, we provide an overview of the currently available knowledge on associations
between myocardial disease, medication and arrest variables on the one hand and VF waveform characteristics (i.e. amplitude, frequency) on the other hand from studies
with  patients.
Measures related to the VF cycle length Measures related to the VF amplitude
Acute myocardial infarction [13–15] = ↓/=
Previous myocardial infarction [13,16–18,22] ↓/= ↓
Increased LV diameter [17] ↓ =
Increased LV mass = ↑/=
Low  LV ejection fraction [33] ↓ Unk
Beta  blockers [28] ↓ Unk
Class III anti-arrhythmic drugs [17] ↓ =
Longer  arrest duration [34,35] ↓ ↓
CPR  [36,37] ↑ ↑
CPR: cardiopulmonary resuscitation, LV: left ventricular, unk: unknown, VF: ventricular ﬁbrillation.
Determinants of the VF waveform
Animal studies
Studies in animals have generated a valuable amount of infor-
mation on determinants of the VF waveform [5,10–12,23–26].
Initial studies primarily focused on the relation with markers of the
metabolic state, e.g. arrest duration or coronary perfusion pressure
[23–26]. More recent studies showed that the presence of an acute
MI  also results in less coarse VF [10,11]. For a history of a previ-
ous myocardial infarction, thus for pre-existent infarction as well, it
has been demonstrated that the course of the VF waveform differs
when compared to VF in a structurally normal heart [11,12].
Human studies
In Table 3, we provide an overview of our current knowledge
on patient-related factors that inﬂuence the electrocardiographic
appearance of the VF waveform. Among the different studies on the
impact of a previous MI,  data are consistent, demonstrating lower
VF amplitude characteristics in the leads adjacent to the area of
infarction [13,16–18]. In contrast, results of the studies on acute MI
yielded contrasting ﬁndings in the setting of OHCA [13–15]. Despite
the frequent occurrence of LV dilatation and hypertrophy, and the
associated increased risk of sudden cardiac death, the impact of the
LV diameter and mass on VF characteristics has so far only scarcely
been studied [27].
Impact of the LV diameter and mass
LV diameter
The dominant and median frequencies were consistently lower
in all analysed ECG-leads in case of an increased LV diameter. This
effect was seen in both patients with and without pre-existent
infarctions and was independent of other variables that are known
to lower VF frequency characteristics (Table 3), as for example
amiodarone and beta blocker use [28]. The dominant frequency
roughly corresponds to the number of ﬁbrillation cycles per sec-
ond and to the reciprocal of the cycle length [29]. In animal hearts,
it has been demonstrated that acute ventricular stretching results in
shortening of the action potential duration and refractory period,
leading to higher dominant frequencies [30,31]. This seems con-
trasting with our observations. However, acute stretching may
not mimic  the human situation in which LV remodelling is often
multifactorial and results from longstanding adaptation to cardiac
overload. In animal hearts, it has been demonstrated that in case
of heart failure remodelling, the VF rate decreases [31]. The latter
is in concordance with our observations and corresponds to the
characteristics of our study population, which mainly consists of
heart failure patients. A mapping study in explanted hearts from
transplant recipients with dilated cardiomyopathy provides fur-
ther insight in the potential underlying mechanism of the altered
VF frequency characteristics [32]. In this study, it was  observed that
areas of ﬁbrosis on histopathologic examination corresponded with
areas of conduction block during VF.
LV mass
Observations with regard to the LV mass were less consistent,
although it seems that an increased LV mass is associated with
higher VF amplitudes. Previously, we have shown that in the pres-
ence of pre-existent infarction, and thus with a loss of depolarizing
mass, VF amplitude characteristics were lower in the adjacent leads
[18]. The present observations seem in line with these ﬁndings as
with an increased cell mass amplitude characteristics were gen-
erally higher, although ﬁndings were not as robust and consistent
as observed for the correlation between LV dilatation and the VF
waveform. This may  relate to local differences in wall thickness
adjacent to the various ECG leads. Unfortunately, our imaging infor-
mation was limited to echocardiography and lacks an advanced
technique like MRI. This could have provided important informa-
tion on the complex alterations in ventricular architecture that
occur with remodelling resulting in coexistence of regions of ﬁbro-
sis and adaptive hypertrophy.
Implications
The present study further completes the current picture with
regard to the impact of pre-existent myocardial disease on char-
acteristics of the VF waveform. It needs to be determined whether
our ﬁndings on short-duration electrically-induced VF also apply to
the OHCA setting. If this is the case, our ﬁndings may  have impor-
tant implications. First, pre-existent myocardial changes may  then
complicate the use of the VF waveform as a mere proxy of arrest
duration or actual metabolic state. As such, it may  inﬂuence the
predictive ability for shock success and outcome. For example, low
amplitude, low frequency VF could represent someone with a long
arrest duration, but could also be indicative of pre-existent myocar-
dial pathology (prior infarction, LV dilatation etc.). Second, it could
explain the contrasting observations in studies that reported on
the impact of acute infarction on the VF waveform. In these stud-
ies, factors like previous infarction, LV mass or diameter were not
accounted for. Third, it should be noticed that the observed inter-
play between the VF waveform on the one hand, and pre-existent
and acute myocardial pathology on the other, is dependent on
the ECG-recording direction. Concluding, our ﬁndings support the
idea that the appearance of the VF waveform on the surface ECG
depends on multiple factors. In this light, more comprehensive
studies on VF characteristics are warranted to investigate if and
how VF-guided resuscitation strategies might improve outcome
after cardiac arrest.
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Limitations
First, although the present study question was retrospectively
deﬁned, data are part of a prospective study project on VF wave-
form analysis [18]. This explains the lack of echocardiographic data
in 13 cases, which resulted in exclusion for this paper. Our project
is performed in a specialised research electrophysiology lab, which
accounts for the fact that this study represents only about half of
our total of ICD implantations. However, as baseline characteristics
of the other half of patients did not differ (Supplementary Table
1), it is unlikely that exclusion of patients has affected our main
ﬁndings. Second, in view of the low number of patients with an
increased LV mass, we were unable to perform in-depth analysis
on a potential gender-dependent relation between LV mass and
VF waveform characteristics. In this context, we used a guideline-
deﬁned categorisation, and corrected for gender in multivariate
analysis. Finally, in- and exclusion of patients with channelopathies
did not result in different study ﬁndings.
Conclusions
Frequency characteristics of the VF waveform were consistently
lower across all ECG-leads in case of an increased LV diame-
ter, with no effect on amplitude characteristics. In contrast, VF
frequencies did not vary according to the LV mass. While less
uniform, amplitude-related measures were slightly higher in case
of an increased LV mass. Further study on pre-existent disease-
related myocardial characteristics that modulate the VF waveform
is warranted to improve our insights into factors which should be
accounted for in future studies on VF-guided resuscitative inter-
ventions.
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